Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine Triacetate SCHEMBL7924235 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL871011 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL19308912 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL12928917 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL19308849 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL12900042 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL14950624 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL10350038 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| Uridine Triacetate SCHEMBL15279673 | 1.00 | LMNA (0.64) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL8904824 | 0.99 | LMNA (0.63) | LMNATHRBSMN1; SMN2HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227993-B2 | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders | TUFTS UNIVERSITY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150265647-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | TUFTS UNIVERSITY | 2015-09-24 | — | — | US | disclosed |
| US-20150045319-A1 | URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | TUFTS UNIVERSITY | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045319-A1 | URIDINE DIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | P2RY6, P2RX6, P2RY1 | LMNA 3136/4885THRB 2734/4885SMN1; SMN2 92/4885 |
| US-20150265647-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | UMPS, UPP1, UGDH | LMNA 2715/4885THRB 2557/4885SMN1; SMN2 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.